Assisted Reproductive Technology Market

Report Overview

The Global Assisted Reproductive Technology Market size is expected to be worth around USD 179.4 Billion by 2033, from USD 31.9 Billion in 2023, growing at a CAGR of 19.4 % during the forecast period from 2024 to 2033.

Assisted Reproductive Technology (ART) encompasses medical techniques aimed at treating infertility, including the widely known In Vitro Fertilization (IVF), where eggs and sperm are combined in a laboratory to create embryos that are subsequently implanted in the uterus. Other methods, such as intracytoplasmic sperm injection (ICSI) and embryo cryopreservation, also form part of ART, aiding individuals and couples facing reproductive challenges. This technology is pivotal in facilitating successful pregnancies for many who encounter difficulties in natural conception.

The Assisted Reproductive Technology (ART) market is primarily oriented towards fertility clinics, hospitals, and research institutes. In 2019, the U.S. reported 330,773 ART cycles resulting in 83,946 births, indicating a robust demand driven by rising infertility rates, advances in technology, and diverse family-building aspirations, including those of single women and same-sex couples. This underscores the importance of ART in contemporary reproductive healthcare.

In terms of regulation, the U.S. market is monitored by the CDC and FDA, ensuring the safety and efficacy of ART procedures, with a notable success rate particularly among younger demographics. Europe adheres to strict standards set by the European Society of Human Reproduction and Embryology (ESHRE), while the Indian government’s Assisted Reproductive Technology (Regulation) Act 2021 aims to enhance care and safety for donors and patients, though it presents challenges such as increased costs and reduced donor availability.

Globally, the U.S. exported fertility-related medical devices worth approximately $1.2 billion in 2020, with key markets in Europe, Asia, and Latin America, highlighting strong global demand and growth potential. Additionally, national initiatives further support the ART market. The UK’s National Health Service (NHS) offers support under specific conditions, and Australia provides Medicare rebates to help manage costs. These efforts reflect increasing governmental involvement aimed at improving ART practices and accessibility.

Strategic developments also play a crucial role in market dynamics. In January 2021, CooperSurgical broadened its ART capabilities by acquiring The Center for Reproductive Medicine in Texas. Similarly, in June 2020, Merck KGaA formed a partnership with Genea Biomedx to advance fertility technologies, reflecting a trend towards enhancing service offerings and success rates through strategic mergers and collaborations.

This sector’s continuous evolution is propelled by technological advancements, regulatory oversight, and strategic industry moves, catering to a growing demographic of individuals seeking reproductive assistance.

Key Takeaways

• The global assisted reproductive technology (art) market is growing with a CAGR of 19.4% during 2023-2032.
• Accessory & disposable-type ART holds the largest market share at 52.3% in 2022.
• In-vitro fertilization is the most lucrative technology segment with an 87% market share in 2022.
• Fresh non-donor procedures are the most lucrative among different procedures, accounting for 40% of the market in 2022.
• Fertility clinics are the dominant end-users, contributing to 40.5% of the market in 2022.
• Technological advancements, such as IVF and ICSI, have improved ART success rates.
• Rising disposable income makes ART more accessible.
• Increasing awareness and government support contribute to growing demand.
• Europe is the most lucrative market with a 39.2% market share.
• Asia Pacific shows rapid growth due to increasing awareness and demand.

Product Analysis

The market for assisted reproductive technology (ART) is segmented into instruments, accessories & disposables, and reagents & media. The accessories & disposables segment is the most lucrative, with a projected CAGR of 19.4%. In 2022, this segment accounted for 52.3% of the total revenue share in the global ART market.

Accessories & disposables include items such as needles, catheters, and culture dishes. These items are used during ART procedures and are disposed of after use. Instruments encompass equipment like incubators, micromanipulators, and imaging systems used in ART procedures. Reagents & media include various chemicals and media that support embryo development and culture during ART procedures.

The high demand for accessories & disposables is driven by their single-use nature, ensuring sterility and reducing the risk of contamination. This factor contributes significantly to their dominance in the ART market. Moreover, continuous advancements in ART procedures and increasing infertility rates globally boost the demand for these products.

Instruments and reagents & media segments also play crucial roles in ART. Instruments provide essential support for precise procedures, while reagents & media are vital for successful embryo culture and development. However, the accessories & disposables segment remains the most profitable, reflecting its critical role in the ART process.

Technology Analysis

The global assisted reproductive technology market is segmented by technology into in-vitro fertilization, artificial insemination, frozen embryo transfer, and other technologies. In 2022, the in-vitro fertilization segment is the most lucrative, holding an 87% market share. It is projected to grow at a CAGR of 19.4%. This segment’s dominance highlights its effectiveness and widespread adoption.

Artificial insemination is another key technology. It involves placing sperm directly into a woman’s cervix, uterus, or fallopian tubes. This method increases the chances of fertilization. Frozen embryo transfer is an IVF technique where embryos not immediately used for implantation are frozen and stored for future use. This technique offers flexibility and better pregnancy planning.

Other technologies in the human reproductive technologies market include gamete intrafallopian transfer, zygote intrafallopian transfer, intracytoplasmic sperm injection, and preimplantation genetic testing. These methods offer diverse options for individuals and couples seeking reproductive assistance. Each technology addresses different fertility challenges, providing tailored solutions.

The market’s growth is driven by increasing infertility rates and advancements in reproductive technologies. The rise in awareness and acceptance of assisted reproductive methods further boosts market expansion. This trend is expected to continue, making assisted reproductive technology a critical component of modern healthcare.

Procedure Analysis

The market for assisted reproductive technology is segmented into fresh non-donor, fresh donor, frozen donor, and frozen non-donor types. Among these, the fresh non-donor segment is the most lucrative, with a projected CAGR of 19.4%. In 2022, the fresh non-donor segment accounted for 40% of the total revenue share in the global assisted reproductive technology market.

Fresh donor cycles are utilized when the female partner cannot produce viable eggs or when there is a risk of genetic disease transmission. The frozen donor procedure involves using frozen eggs and embryos from a donor. It may also use fresh sperm from the male partner or a sperm donor for fertilization. This method is often chosen for its convenience and scheduling flexibility.

The frozen non-donor procedure uses frozen eggs or embryos from the female partner and fresh sperm from the male partner for fertilization. Each procedure offers unique advantages and disadvantages. Couples choose the most suitable option based on their specific needs and preferences.

The assisted reproductive technology market is expanding rapidly. The increasing success rates and technological advancements drive this growth. The market is expected to continue its upward trajectory, offering more couples the chance to conceive.

End-User Analysis

The global assisted reproductive technology (ART) market is segmented by end-user into fertility clinics, hospitals, surgical centers, clinical research institutes, and other end-users. Among these, the fertility clinic segment holds the largest revenue share of 40.5% and is projected to have a CAGR of 19.4% during the forecast period.

Fertility clinics are specialized centers focusing on infertility diagnosis and treatment. Hospitals offer a range of healthcare services, including ART procedures. Surgical centers provide outpatient surgical procedures, including some ART services. Clinical research institutes focus on developing new treatments and technologies in reproductive medicine.

The choice of end-user depends on several factors. These include the availability of specialized services, the expertise and experience of healthcare providers, and the cost of procedures. Fertility clinics are preferred for their specialized services and expertise. Hospitals are chosen for their comprehensive healthcare services. Surgical centers are selected for their convenience in providing outpatient procedures. Clinical research institutes are essential for advancing ART treatments through research.

Key Market Segments

Based on Type

• Instrument
  • Sperm Separation System
  • Cryosystem
  • Incubator
  • Imaging System
  • Ovum Aspiration Pump
  • Cabinet
  • Micromanipulator
  • Laser Systems
  • Others
• Accessory & Disposable
• Reagents & Media
  • Cryopreservation Media
  • Semen Processing Media
  • Ovum Processing Media
  • Embryo Culture Media

Based on Technology

• In Vitro-Fertilization
• Artificial Insemination
• Frozen Embryo Transfer
• Other Technologies

Based on Procedure

• Fresh Donor
• Fresh Non-donor
• Frozen Donor
• Frozen Non-donor

Based on End-User

• Fertility Clinic
• Hospital
• Surgical Center
• Clinical Research Institute
• Other End-Users

Drivers

Technological Advancements & Rising Disposable Income in the ART Market

Recent enhancements in assisted reproductive technology (ART), notably in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), have significantly improved success rates. This progress broadens the potential patient base capable of benefiting from these procedures. Concurrently, the rise in disposable income globally has enabled a larger demographic to afford these often costly treatments, thereby expanding access and adoption. For instance, the U.S. reported a 0.5% real increase in disposable personal income in May 2024, following stability in April​ (BEA)​.

Increasing Awareness and Government Support for the ART Market

Awareness of ART’s possibilities and their success rates is increasing among potential patients and healthcare providers, fueling a higher demand for these services. This growing awareness, coupled with governmental financial support in certain countries, has made ART procedures more accessible to a broader array of patients. Such policy initiatives aim to alleviate the financial burdens associated with ART, facilitating easier access for individuals seeking fertility treatments

Restraints

Ethical and Operational Challenges in Assisted Reproductive Technology (ART)

Assisted Reproductive Technology (ART) procedures, encompassing treatments such as IVF and surrogacy, present significant ethical dilemmas. Ethical concerns often revolve around the use of donor gametes and the moral implications of embryo selection. According to the American Society for Reproductive Medicine, these ethical issues can deter some patients and healthcare providers from opting for these procedures.

Furthermore, the physical and emotional toll of ART, requiring extensive medical appointments, treatments, and medications, poses another significant barrier. Data from the Centers for Disease Control and Prevention (CDC) indicate that the rigorous demands of these treatments lead to a discontinuation rate of approximately 20% among patients, underscoring the need for increased support and clearer ethical guidelines in this sector.

Opportunity

Advancements in Technology and Expansion of the ART Market

Technological advancements in assisted reproductive technology (ART), including genetic testing and embryo selection, are enhancing the efficacy of ART procedures. These advancements not only improve success rates but also broaden the scope of ART to encompass fertility preservation, egg freezing, and surrogacy. This expansion diversifies the ART market, creating new growth opportunities beyond conventional infertility treatments. For example, in 2021, nearly 41% of ART cycles involved egg or embryo banking, highlighting a significant shift towards preserving reproductive potential for future use​.

Increasing Government Support and Emerging Markets

Government interventions are increasingly facilitating access to ART, with some nations offering financial support to make these procedures more accessible to a broader demographic. This support is pivotal in emerging markets, where the demand for ART is on the rise but access remains limited. As of 2021, the Centers for Disease Control and Prevention reported that approximately 238,126 patients underwent ART cycles in the U.S., illustrating the growing utilization of these services. Additionally, the success rates and extensive use of techniques such as in vitro fertilization (IVF) underscore the significant role of government-backed initiatives in promoting reproductive health technologies​.

Trends

Regional Analysis

Europe is the most lucrative market in the global assisted reproductive technology (ART) sector. It holds the largest market share at 39.2%. During the forecast period, it is expected to register a CAGR of 19.4%. Asia Pacific is a rapidly growing market for ART. This growth is driven by increasing awareness, demand, and investment in reproductive healthcare.

Countries like China, India, and Japan have large populations and growing middle classes. These factors drive the demand for infertility treatment services. North America is a mature market for ART. It has high levels of awareness, adoption, and investment in reproductive healthcare. The Middle East and Africa are relatively underdeveloped markets for ART. These regions face limited access to healthcare services. Cultural or regulatory barriers also hinder adoption.

The ART market’s growth in Europe is significant due to substantial investment and favorable regulations. In contrast, Asia Pacific’s growth is fueled by rising awareness and demand. North America maintains its position due to strong investment and widespread adoption. Meanwhile, the Middle East and Africa struggle with regulatory and cultural challenges. However, potential growth opportunities exist with improving healthcare access. Overall, the global ART market is expanding, with varying growth dynamics across regions.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

The market share of key players in the assisted reproductive technology market varies by region, product offerings, and competitive landscape. However, certain companies are recognized as leaders in this market. These companies have strong brand recognition, extensive distribution networks, and a proven track record of innovation.

Cosmos Biomedical Ltd is known for its advanced technologies and comprehensive solutions. Microm U.K. Ltd offers a wide range of products that cater to various needs within the market. CooperSurgical, Inc has established itself as a prominent player through consistent innovation and quality products.

FUJIFILM Irvine Scientific is another major player, renowned for its cutting-edge technologies and reliable products. Cryolab Ltd has gained a strong market presence due to its specialized services and innovative solutions. These companies, along with other key players, dominate the market with their strong distribution networks and continuous advancements in technology.

Their success is attributed to their ability to meet the growing demands of the market, ensuring quality and reliability. Their extensive research and development efforts have led to significant innovations, keeping them at the forefront of the industry. Overall, these companies continue to lead the assisted reproductive technology market, maintaining strong positions through their strategic initiatives and robust market presence.

Market Key Players

• Cosmos Biomedical Ltd.
• Microm U.K. Ltd.
• CooperSurgical, Inc.
• FUJIFILM Irvine Scientific
• Cryolab Ltd.
• Vitrolife AB
• European Sperm Bank
• Bloom IVF Centre
• Merck KGaA
• Ferring B.V.
• Cook Medical Inc.
• Fujifilm Holdings Corporation
• Genea Biomedx
• Thermo Fisher Scientific, Inc.
• Millendo Therapeutics, Inc.
• Oxford Gene Technology
• Progyny Inc.
• Other Key Players

Recent Developments

• March 2024: Merck KGaA introduced a new line of fertility drugs to improve in vitro fertilization (IVF) outcomes. These drugs are developed to increase the efficacy rates of embryo implantation during IVF procedures.
• In June 2023: CooperSurgical acquired a smaller biotech firm specializing in fertility-enhancing technologies. This acquisition aims to expand CooperSurgical’s product portfolio and enhance its market position in the assisted reproductive technology (ART) sector.
• In February 2023: Vitrolife AB launched a new imaging system to improve the selection process of viable embryos for IVF. The system uses advanced AI algorithms to predict embryo viability more accurately, potentially increasing IVF success rates.
• In January 2023: Cryolab Ltd. introduced a revolutionary cryopreservation technology that enhances the survival rate of frozen embryos and sperm. This makes Cryolab a competitive entity in the ART market by improving options for long-term fertility planning.
• In June 2022: FUJIFILM Irvine Scientific expanded operations by opening a new manufacturing facility in Tilburg, Netherlands. This facility mirrors the quality systems and expertise found in their US and Japanese operations, ensuring global continuity in product quality and innovation.

Report Scope